De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

Absci Beheer

Beheer criteriumcontroles 2/4

De CEO Absci's is Sean McClain, benoemd in Aug2011, heeft een ambtstermijn van 13.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 3.10M, bestaande uit 20% salaris en 80% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 7.61% van de aandelen van het bedrijf, ter waarde $ 33.00M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.9 jaar en 1.7 jaar.

Belangrijke informatie

Sean McClain

Algemeen directeur

US$3.1m

Totale compensatie

Percentage CEO-salaris	20.0%
Dienstverband CEO	13.2yrs
Eigendom CEO	7.6%
Management gemiddelde ambtstermijn	1.9yrs
Gemiddelde ambtstermijn bestuur	1.7yrs

Recente managementupdates

Recent updates

Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile

Oct 03

Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships

Jul 28

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

Jan 10

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

Jul 22

Analyse CEO-vergoeding

Hoe is Sean McClain's beloning veranderd ten opzichte van Absci's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$92m
Mar 31 2024	n/a	n/a	-US$109m
Dec 31 2023	US$3m	US$620k	-US$111m
Sep 30 2023	n/a	n/a	-US$106m
Jun 30 2023	n/a	n/a	-US$112m
Mar 31 2023	n/a	n/a	-US$99m
Dec 31 2022	US$4m	US$600k	-US$105m
Sep 30 2022	n/a	n/a	-US$111m
Jun 30 2022	n/a	n/a	-US$107m
Mar 31 2022	n/a	n/a	-US$121m
Dec 31 2021	US$4m	US$505k	-US$103m
Sep 30 2021	n/a	n/a	-US$84m
Jun 30 2021	n/a	n/a	-US$73m
Mar 31 2021	n/a	n/a	-US$48m
Dec 31 2020	US$1m	US$260k	-US$49m

Compensatie versus markt: De totale vergoeding ($USD 3.10M ) Sean } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).

Compensatie versus inkomsten: De vergoeding van Sean is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Sean McClain (34 yo)

13.2yrs

Tenure

US$3,097,371

Compensatie

Mr. Sean Mcclain is the Founder of Absci Corporation (formerly known as AbSci, LLC) and serves as its Chief Executive Officer since August 2011 and Director since its formation in October 2020. Mr. Mcclain...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Sean McClain	Founder	13.2yrs	US$3.10m	7.61% $ 33.5m
Zachariah Jonasson	Chief Business Officer & CFO	1.2yrs	US$2.20m	0.071% $ 311.9k
Andreas Busch	Chief Innovation Officer & Member of Scientific Advisory Board	2yrs	US$2.15m	0% $ 0
Todd Bedrick	Senior VP & Chief Accounting Officer	2.3yrs	geen gegevens	0.0026% $ 11.6k
Alexander Khan	VP of Finance & Head of Investor Relations	1.6yrs	geen gegevens	geen gegevens
Shelby Walker	Chief Legal Officer	less than a year	geen gegevens	geen gegevens
Karin Wierinck	Chief People Officer	1.8yrs	geen gegevens	geen gegevens
Melissa Patterson	Chief of Staff	2.6yrs	geen gegevens	geen gegevens
Jens Plassmeier	Senior VP of Biologics Discovery Technology	2.8yrs	geen gegevens	geen gegevens
Wen Sha	Chief of Staff	2.8yrs	geen gegevens	geen gegevens
Christine Lemke	Senior Vice President of Portfolio & Growth Strategy	1.7yrs	geen gegevens	geen gegevens
Christian Stegmann	Senior Vice President of Drug Creation	1.7yrs	geen gegevens	geen gegevens

1.9yrs

Gemiddelde duur

50yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ABSI wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Sean McClain	Founder	4yrs	US$3.10m	7.61% $ 33.5m
Andreas Busch	Chief Innovation Officer & Member of Scientific Advisory Board	less than a year	US$2.15m	0% $ 0
Karen McGinnis	Lead Independent Director	4.2yrs	US$169.46k	0.013% $ 58.2k
François van Houten	Independent Director	1.3yrs	US$171.92k	0% $ 0
Daniel Rabinovitsj	Independent Director	1.9yrs	US$96.37k	0% $ 0
Timothy Lu	Member of Scientific Advisory Board	1.7yrs	geen gegevens	geen gegevens
Menelas Nicolas Pangalos	Independent Director & Member of Scientific Advisory Board	less than a year	geen gegevens	0% $ 0
Joseph Sirosh	Independent Director	2.8yrs	US$101.59k	0% $ 0
Amrit Nagpal	Independent Director	4yrs	US$108.87k	0% $ 0
Victor Greiff	Member of Scientific Advisory Board	1.7yrs	geen gegevens	geen gegevens
Hubert Truebel	Member of Scientific Advisory Board	1.7yrs	geen gegevens	geen gegevens

1.7yrs

Gemiddelde duur

57yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ABSI wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.7 jaar), wat duidt op een nieuw bestuur.

Absci Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Chief Business Officer & CFO notifies of intention to sell stock

Chief Business Officer & CFO notifies of intention to sell stock

Absci Corporation Appoints Menelas Pangalos as Class II Director and Member of Compensation Committee of the Board, Effective January 1, 2024

Absci Corporation Announces Resignation of Sarah Korman as Chief Legal Officer and Interim Chief Business Officer, Effective as of September 15, 2023

Absci Corporation Appoints Zach Jonasson as Chief Business Officer, Effective from August 31, 2023

Absci Corporation Appoints Frans Van Houten to Its Board of Directors

Recent updates

Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships

Absci Corporation to Report Q2, 2024 Results on Aug 14, 2024

Is Absci (NASDAQ:ABSI) A Risky Investment?

Chief Business Officer & CFO notifies of intention to sell stock

Chief Business Officer & CFO notifies of intention to sell stock

Consensus revenue estimates decrease by 26%

Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Absci Corporation to Report Q1, 2024 Results on May 14, 2024

Consensus revenue estimates fall by 20%

Full year 2023 earnings: EPS in line with expectations, revenues disappoint

Consensus revenue estimates decrease by 13%

New minor risk - Shareholder dilution

Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million.

Absci Corporation has filed a Follow-on Equity Offering in the amount of $75 million.

Absci: Differentiated Antibody Discovery Play

Absci Initiates IND-Enabling Studies for Abs-101, A Potential Best-In-Class Anti-Tl1a Antibody De Novo Designed and Optimized Using Generative Ai

Absci Corporation to Present Preclinical Data for ABS-101, A Potential Best-In-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference

Absci Corporation Appoints Menelas Pangalos as Class II Director and Member of Compensation Committee of the Board, Effective January 1, 2024

Price target decreased by 14% to US$5.76

Consensus revenue estimates decrease by 42%

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 15% to US$5.50

Consensus EPS estimates fall by 21%, revenue upgraded

Absci Corporation Announces Resignation of Sarah Korman as Chief Legal Officer and Interim Chief Business Officer, Effective as of September 15, 2023

Absci Corporation Appoints Zach Jonasson as Chief Business Officer, Effective from August 31, 2023

Absci Corporation Reports Impairment Results for the Second Quarter Ended June 30, 2023

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Absci Corporation and California Institute of Technology Join Forces, Bolstered by Major Grant, to Accelerate Affordable HIV Therapeutic Vaccine Development

New major risk - Share price stability

Absci Corporation Appoints Frans Van Houten to Its Board of Directors

Price target decreased by 10% to US$7.73

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Casdin Capital Engages in Discussions with Absci Corporation

Price target decreased by 28% to US$8.60

Consensus revenue estimates decrease by 23%, EPS upgraded

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Casdin Capital Engages in Discussions with Absci Corporation

Absci Deepens Scientific Advisory Board to Accelerate Generative AI Drug Creation

Absci Corporation Announces Ability to Create and Validate de novo Antibodies in Silico with Use of Zero-Shot Generative AI

Consensus forecasts updated

Price target decreased to US$12.10

High number of new and inexperienced directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Absci Corporation Appoints Dan Rabinovitsj as Newest Member of its Board of Directors

Chief Financial Officer exercised options to buy US$155k worth of stock.

Absci Corporation Appoints Veteran Pharma Executive Andreas Busch, PhD as Chief Innovation Officer

Absci Corporation Announces End of Nikhil Goel as Chief Strategy Officer

Price target decreased to US$13.10

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Absci GAAP EPS of -$0.32 misses by $0.01, revenue of $1M misses by $0.68M

Eli Casdin Resigns from Board of Directors of Absci Corporation

Absci teams up to help develop antibody drugs for cancer

Absci Corporation(NasdaqGS:ABSI) dropped from Russell 2000 Growth Index

First quarter 2022 earnings: EPS and revenues miss analyst expectations

High number of new and inexperienced directors

Consensus EPS estimates fall by 29%

Consensus revenue estimates fall by 17%

Merck And Absci: AI-Driven Drug Development Deal Has Promise, But May Take Years To Pay Out

High number of new and inexperienced directors

Third quarter 2021 earnings released: US$0.33 loss per share

Absci, CORP has completed an IPO in the amount of $200 million.

IPO Day With Absci CEO Sean McClain - The Google Of Synthetic Biology (Video)

Analyse CEO-vergoeding

CEO

Tenure

Compensatie